The Economic Times
12,248.2567.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

PTI|
Jan 01, 2019, 12.25 PM IST
0Comments
BCCL
pharma-generic
Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.
NEW DELHI: Shilpa Medicare Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers.

The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.

Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million.

Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

Also Read

USFDA inspects Alembic Pharma's facility in Karkhadi, Gujarat

Cipla announces closure of USFDA inspection at Patalganga facility

Strides gets USFDA nod for anti-allergic drug

Aurobindo Pharma tanks on USFDA observations

Lupin gets USFDA nod to market skin ointment

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service